Risk Classification: How Classes I, IIa, IIb and III Drive Compliance Cost

This article is number 06 in Volume 1, Regulatory Framework and Fundamentals, of the fifty-part series on medical device registration in Switzerland. Together with the other nine articles in this volume it forms a complete deliverable on this topic. The publication timestamp, article number, article title and unique URL are listed in the table below.

1. Key takeaways

Classification is not a label but the master switch for cost and time. MedDO Art. 15 establishes the four classes I, IIa, IIb and III and applies Annex VIII of the EU MDR together with the implementing act in Annex 5a of MedDO. The classification result simultaneously determines whether a third party must be involved in conformity assessment, which transition period milestone applies, and the scale of expenditure for device registration and hourly fees. A single step up or down in class therefore moves several budget lines at once, and classification errors discovered late are among the most expensive corrections in a Swiss market entry project. Any reclassification after submission triggers a cascade across notified body contracts, registration records and labelling, so the class should be confirmed before any of those steps is committed.

2. Legal basis

Verification entry points: MedDO Article 15, Annex 5a and the classification rules of EU MDR Annex VIII; the two sets of rules must be checked in parallel. Because the Swiss rule set operates through citation plus an implementing act, a classification conclusion is only complete when it names both the Annex VIII rule applied and the version of MedDO from which the citation is taken.

3. Expert insights

1. The rules are European, but their application is Swiss. Art. 15 achieves classification through citation of EU MDR Annex VIII and the implementing act in Annex 5a. Conclusion: rule interpretation can follow EU implementing acts and guidance, but any external claim of compliance must rest on MedDO Art. 15 with its version date. The trade-off: following EU interpretation keeps the Swiss file consistent with the CE documentation, at the cost of managing the Swiss version difference as a separate workstream. Both texts should be stored together in the technical file so that reviewers can verify the Swiss basis without searching.
2. Classification determines three accounts at once. Conformity assessment: Art. 23 in combination with EU MDR Art. 52 means reusable surgical instruments require a notified body certificate under the MDR. Transition periods: MedDO high-risk devices run until 31 December 2027 and medium and low risk devices until 31 December 2028; codes certificates issued between 25 May 2017 and 25 May 2022 remain valid until 31 December 2027. Fees: the CHRN fixed fee under Annex II is CHF 200; device registration is CHF 200 for the first UDI-DI and CHF 20 for each additional UDI-DI in the same year; the hourly fee rate is CHF 270 per working hour from 1 July 2026. Conclusion: a single step up in class changes third-party involvement, time windows and fees simultaneously, so all three accounts must be computed together. A comparison table per class, populated with these figures, is the fastest way to present the consequences of a borderline classification to management.
3. The abolition of sell-off changes inventory strategy. Both MedDO and IvDO have removed sell-off arrangements. Conclusion: after the end of a transition period there is no statutory window to deplete old stock, so production and import plans must be scheduled backwards from the transition deadline. The counterpoint: relying on a sell-off period to clear inventory has no basis on the Swiss side, and hoping that EU-side arrangements will apply equally does not work for the Swiss market.

4. Practical recommendations

1. Record the classification conclusion under Art. 15 with the number of each applicable Annex VIII rule; never substitute a product description for a rule citation.
2. Lock the transition period milestone as soon as classification is fixed, and schedule production, import and documentation switching backwards from that date.
3. For classes requiring third-party involvement, book notified body capacity early; never leave this step to the end of the transition period.
4. Estimate registration fees by the number of UDI-DIs, including the first CHF 200 and CHF 20 for each additional one as annual expenditure.
5. Whenever classification changes, review the conformity assessment route, CHRN information and technical documentation versions together.

5. Verification checklist

• □ The classification conclusion states the applicable Annex VIII rule numbers and the MedDO version date
• □ The transition milestone is locked by class (31 December 2027 or 31 December 2028)
• □ Notified body capacity is booked for classes requiring third-party involvement
• □ Registration fees are estimated by UDI-DI count and included in the budget
• □ Hourly fees have been recalculated at CHF 270 per hour
• □ Review triggers for classification changes are defined in the quality management system

Regulatory information verified as of 29 October 2026.

GRZAN supports manufacturers and economic operators entering the Swiss market with end-to-end Swissmedic registration and compliance services, including classification assessments under MedDO Art. 15 and Annex VIII, transition period planning, notified body strategy, and fee modelling under FeeO-Swissmedic. Our team turns a classification decision into a complete cost and schedule picture. For tailored guidance on your product portfolio, contact info@grzanglobal.com.